Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection

Andrea M Isidori,Riccardo Pofi,Valeria Hasenmajer,Andrea Lenzi,Rosario Pivonello

doi:10.1016/s2213-8587(20)30149-2

Abstract

Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection

Highlights

In March 2020, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), reached pandemic level with a high global mortality rate.[1]
The initial immune response to viral load is followed by an uncontrolled cytokine storm with hyperinflammation and immunosuppression
In critical illness, HPA activation might be blunted, leading to corticosteroid insufficiency related to critical illness.[2]

Summary

Introduction

In March 2020, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), reached pandemic level with a high global mortality rate.[1]. This low rate of residual β-cell function was expected given our safety-driven strategy of choosing only patients with long standing type 1 diabetes (on average more than 12 years with the disease) for this first-in-man trial.

Results

Conclusion